A ₹2,279.50 crore block deal has been launched in Gland Pharma Ltd on Thursday (September 3), with Fosun Pharma Industrial as the seller. According to reports from NDTV Profit and The Economic Times, the deal represents 5% of the company's total equity at a floor price of ₹2,763 per share, representing a 5% discount to the stock's prevailing market price. At ₹2,763 per share, the block deal price implies a discount of around ₹145 per share to Thursday's closing price of ₹2,907.90. The transaction also carries a 12-month lock-up on any further sale of shares. Fosun Pharma Industrial holds 8,53,93,894 shares or 51.77% stake in the pharmaceutical company as of the quarter ended June 30, 2026, as per BSE data.
Gland Pharma reported robust financial results for Q1 FY27, with net profit increasing 47.1% year-on-year to ₹317 crore compared with ₹215 crore in the corresponding quarter last year. As reported by CNBC TV18 and The Economic Times, revenue grew 19.6% year-on-year to ₹1,800.2 crore from ₹1,505.6 crore in Q1 FY6. EBITDA rose 33.1% year-on-year to ₹489.2 crore from ₹367.6 crore, with EBITDA margin improving to 27.2% compared with 24.4% in the year-ago quarter. Adjusted EBITDA margin stood at 28%. During Q1FY27, Gland Pharma's quarterly R&D investment stood at ₹77.2 crore, while adjusted EBITDA increased 37% year-on-year.
The company's diversified business model showed strong performance across segments. According to CNBC TV18 and The Economic Times, the contract development and manufacturing organisation (CDMO) business contributed 50% of revenues and grew 20% year-on-year in Q1 FY27. The business-to-business (B2B) business also contributed 50% of revenues and grew 19% year-on-year. The company's research and development expenditure stood at ₹772 million, accounting for 4% of consolidated revenue, focused on complex product development and filings.
Gland Pharma made significant progress in the US market during the quarter. As reported by CNBC TV18 and The Economic Times, the company launched four molecules in the US during Q1 FY27, including Multi-Vitamin and Leucovorin calcium. The company filed three abbreviated new drug applications (ANDAs) and received seven approvals in Q1 FY27, taking its cumulative US ANDA filings to 389, comprising 342 approved applications and 47 pending applications. The company also launched six products in its in-house complex pipeline while three more are in line for approval.
Gland Pharma shares closed 1.39% higher at ₹2,904.85 on Thursday following the announcement, with the stock gaining 1.39% over the past week and 69.96% year-to-date. According to NDTV Profit and The Economic Times, the stock has delivered a strong return of 69.96% year-to-date and 55.32% over the past year, significantly outpacing recent weekly performance. The pharma counter traded in the range of ₹2,929.90 to ₹2,850.00 during the day. The company has a market capitalisation of ₹47,920.34 crore on the BSE as of September 3, 2026. From a technical perspective, Gland Pharma's 50-day moving average stands at ₹2,615.95, with the proposed block deal price of ₹2,763 above the stock's 50-DMA despite remaining at a discount to current market price.
